Side-by-side comparison of AI visibility scores, market position, and capabilities
Practice analytics and patient engagement platform for dental offices helping DSOs and independents grow production. American Fork UT; founded 2016; connects to 100+ dental PMS systems;
Dental Intelligence is an American Fork, Utah-based dental practice analytics and patient engagement platform that helps dental offices, group practices, and dental support organizations (DSOs) analyze production data, identify growth opportunities, and improve patient engagement and retention. Founded in 2016, the company built its platform around a core insight: most dental practices generate enormous amounts of operational data in their practice management software but lack the tools to turn that data into actionable insights. Dental Intelligence connects to over 100 dental practice management systems—including Dentrix, Eaglesoft, OpenDental, and Carestream—and automatically analyzes key performance indicators including production per provider, case acceptance rates, recall effectiveness, hygiene reappointment rates, and collections performance.\n\nThe platform's patient engagement tools allow dental practices to automate appointment reminders, recall outreach, and reactivation campaigns for patients who are overdue for cleanings or who have unscheduled treatment plans. These engagement automations reduce the manual administrative burden on front desk staff while improving patient show rates and reducing last-minute cancellations that disrupt production schedules. Dental Intelligence's analytics layer surfaces the specific operational levers most likely to drive revenue growth for each practice—whether that is improving treatment plan acceptance, filling hygiene chairs more efficiently, or reducing same-day cancellations.\n\nDental Intelligence has found particular traction with multi-location DSO customers that need consistent performance analytics and benchmarking across dozens or hundreds of dental practices. The platform's DSO-tier dashboards allow regional managers and corporate leadership to compare location performance, identify underperforming practices, and replicate the operational practices of top performers. The company competes with Weave, Solutionreach, and Carestream Dental in the dental technology market, differentiating on the depth of its practice analytics and its broad integration with existing dental practice management systems.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.